

Synthesis of pyrazolo[1,5-*a*]pyrimidine ring as a possible bioisosteric replacement of the 5-(1*H*-pyrrol-1-yl)pyrazole scaffold

Claudia Mugnaini, Livia Pasculini, Carlotta Pagli, Antonella Brizzi, Marco Paolino, Beatrice Gianibbi, and Federico Corelli*

Department of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100 Siena, Italy
Email: federico.corelli@unisi.it

It is a pleasure to take this opportunity to acknowledge the significant contribution to the chemistry of heterocyclic compounds by Professor Girolamo (Gilmo) Cirrincione and his Palermo group


Received 09-02-2021

Accepted Manuscript 10-03-2021

Published on line 10-09-2021

Abstract

Reaction of 3-amino-1*H*-pyrazole-4-carbonitrile with 2,4-pentanedione yielded 5,7-dimethylpyrazolo[1,5-*a*]pyrimidine-3-carbonitrile, which was easily and efficiently transformed into a small library of amido derivatives. This procedure opens the way to new compounds potentially endowed with interesting biological activities



Keywords: Pyrazolo[1,5-*a*]pyrimidine, bioisosteric replacement, Suzuki coupling, conformational analysis

Introduction

Heterocyclic compounds with pyrrole and pyrazole structures have aroused increasing interest over time both for their relevance among natural compounds and for their assessed or potential applications in the pharmaceutical field, as demonstrated by some noteworthy contributions in the recent literature.¹⁻³




Figure 1. Lead compound **1**, general structure of the new compounds **2**, and graphical representation of the global minimum conformation of **2** (X = H). The hydrogen bond between the N4 and the amide NH is represented by a dashed green line.


Over the years we have thoroughly studied the synthesis and chemical and pharmacological properties of 3-/ 5-pyrrolylpyrazoles.⁴⁻⁷ Very recently, through a screening campaign aimed at discovering new antibacterial agents, we identified derivative **1** (Figure 1) as a compound endowed with synergistic activity with the known antibiotic colistin.⁸ The significant results obtained prompted us to explore structural modifications of **1**. In particular, we focused on the replacement of the 5-(1*H*-pyrrol-1-yl)pyrazole scaffold with the condensed pyrazolo[1,5-*a*]pyrimidine heterocycle, as exemplified by compounds **2** (Figure 1), where position 3 was prioritized as the point of structural divergence.

As shown in previous papers for compounds similar to **1**,⁴⁻⁶ pyrazole and pyrrole rings in compound **1** are far from being coplanar, whereas a pyrazolo[1,5-*a*]pyrimidine nucleus is expected to ensure the planarity not only of the 10 π -electron heterocycle but also of a wider molecular area as a result of a H-bond interaction between the NH of the amide group and the nitrogen at the position 4.⁹ This intramolecular hydrogen bond will also help reduce the conformational freedom of the new compounds, thus introducing significant alterations of the three-dimensional structure of the molecule. Furthermore, we wanted to explore the possibility of functionalizing compounds **2** with specific amide residues in analogy to what has been recently described by Lu *et al.* to obtain pyrazolo[1,5-*a*]pyridine-3-carboxamides with significant antimycobacterial activity.¹⁰

Results and Discussion


Preliminary molecular modeling studies have referred to the unsubstituted *N*-benzyl-5,7-dimethylpyrazolo[1,5-*a*]pyrimidine-3-carboxamide (Figure 1, X =H). Conformational analysis identified several conformational minima that show a very similar three-dimensional arrangement with the N4---HN distance between 2.20 and 2.23 Å, and the NH-N4 angle between 133.9 and 139.6 degrees, comparable to that reported in the literature for similar compounds (i.e., 2.06 Å and 134.7 degrees found for the 6-methyl-*N*-[(1*R*)-1-[4-(trifluoromethoxy)phenyl]propyl]pyrazolo[1,5-*a*]pyrimidine-3-carboxamide co-crystallized to the human PDE2A, entry 5xkm of the protein data bank), and in agreement with geometric criteria of the existence of the NH---N hydrogen bond.¹¹

For the synthesis of the bicyclic compounds **2**, 2,4-pentanedione was reacted with 3-amino-1*H*-pyrazole-4-carbonitrile (**3**), affording 5,7-dimethylpyrazolo[1,5-*a*]pyrimidine-3-carbonitrile (**4**) as a pure crystalline solid in 78% yield (Scheme 1). The subsequent hydrolysis of the nitrile to carboxylic acid **5** was best accomplished by refluxing **4** in ethylene glycol with NaOH overnight. As a whole, the conversion of **3** to **5** was performed with a satisfactory 55% overall yield, comparable to that reported by Patnaik *et al.*¹²



Scheme 1. Reaction of compound **3** with 2,4-pentanedione and subsequent hydrolysis to carboxylic acid.

With compound **5** in our hands, the amides **2a** and **2b** (Scheme 2) were synthesized with yields of 85% and 65%, respectively, and then subjected to further modification by Suzuki reactions. Thus, reaction with 4-formylphenylboronic acid **2a** provided compound **6**, which was directly reduced with NaBH₄ to obtain alcohol **2c** in an overall yield of 48%. Compounds **2d-f** were synthesized from **2b** by the action of the appropriate boronic acid, namely 3-pyridinylboronic acid, 3-acetamidophenylboronic acid, and 4-(trifluoromethoxy)phenylboronic acid, respectively, in 25-67% yield. All these coupling reactions were conducted under conventional heating, because the use of microwaves as an alternative way gave products in lower yield (for **2d**, as an example, 24% yield instead of 50%).



Scheme 2. Synthesis of a small library of 5,7-dimethylpyrazolo[1,5-*a*]pyrimidine-3-carboxamides.

Conclusions

Taking compound **1** as a model, an efficient synthetic pathway for functionalization of the pyrazolo[1,5-*a*]pyrimidine scaffold was explored and developed. The results obtained, exemplified by compounds of general structure **2**, testify to the possibility of extending this class of heterocyclic compounds into larger libraries in view of their possible biological evaluation.

Experimental Section

General. Merck silica gel 60 was used for flash chromatography (23-400 mesh). For thin layer chromatography (TLC), silica-coated aluminum plates (Merck Kieselgel F₂₅₄) were used. Melting points were determined on a Gallenkamp apparatus and are uncorrected. ¹H NMR and ¹³C NMR were recorded on a Bruker Avance DPX400 or Bruker Avance 600 spectrometers operating at 400/100 MHz or 600/150 MHz, respectively. Chemical shifts δ are in part per million (ppm) relative to TMS as internal standard and coupling constants (*J*)

are reported in Hz (in the attribution of the signals reference is made to the numbering of the bicyclic system reported in Figure 1). Mass spectral (MS) data were obtained using an Agilent 1100 LC/MSD VL system (G1946C) with a 0.4 mL/min flow rate using a binary solvent system of 95:5 methanol/water. UV detection was monitored at 254 nm. Elemental analyses were performed with a Perkin-Elmer PE 2400 elemental analyzer and the data for C, H, and N are within 0.4% of the theoretical values. The chemical purity of the target compounds was determined using an Acquity Waters UPLC-MS system under the following conditions: Waters BEH C18 (2.1 mm x 50 mm, 1.7 μ m) reversed phase column; method: gradient elution, solvent A (0.1% formic acid in water), solvent B (0.1% formic acid in acetonitrile) 90:10 to 0:100 over 2.9 min, flow rate of 0.5 mL/min, UV detector, 254 nm. Infrared spectra were recorded on the crystalline powder using an Agilent Cary 630 ATR-FTIR instrument. Microanalyses were performed on a Perkin-Elmer PE 2400 analyzer.

Synthesis of 5,7-dimethylpyrazolo[1,5-*a*]pyrimidine-3-carbonitrile (4). A mixture of 3-amino-1*H*-pyrazolo-4-carbonitrile (**3**) (300 mg, 2.8 mmol) and 2,4-pentanedione (4-5 mL) was heated at 180 °C for 3 h. The solid product that formed on cooling to room temperature was triturated with hexane and recrystallized from EtOH to give **4** as a white solid (373 mg, 78%). Mp 175-176 °C; FT-IR $\nu_{\text{max}}/\text{cm}^{-1}$ 3119, 3064, 2228 (CN), 1625 (C=N), 1556, 1423; ¹H NMR (600 MHz, CDCl₃) δ 8.31 (s, 1H, H-2), 6.81 (s, 1H, H-6), 2.79 (s, 3H, Me), 2.66 (s, 3H, Me); ¹³C NMR (150 MHz, CDCl₃) δ 163.1, 150.2, 146.9, 146.7, 113.2, 111.2, 81.9, 24.8, 17.0; MS (ESI) m/z 173 [M + H]⁺; Found: C, 62.59; H, 4.73; N, 32.68. C₉H₈N₄ requires C, 62.78; H, 4.68; N, 32.54%.

Synthesis of 5,7-dimethylpyrazolo[1,5-*a*]pyrimidine-3-carboxylic Acid (5). An aqueous 3 N solution of NaOH (12 mL, 36 mmol) was added to a suspension of **4** (1.2 g, 7.0 mmol) in ethylene glycol (20 mL) and the mixture was heated at reflux overnight. After cooling, the reaction mixture was diluted with water, acidified with conc. HCl, and extracted with EtOAc (7 x 20 mL). The organic phase was dried over sodium sulfate and evaporated to afford a yellow solid, which was recrystallized from EtOH. The title compound **5** was obtained as a yellowish solid (930 mg, 70%). Mp 178-180 °C; FT-IR $\nu_{\text{max}}/\text{cm}^{-1}$ 3200-2400 (broad band, COOH), 1625 (C=O), 1553 (C=N); ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.41 (s, 1H, H-2), 6.99 (s, 1H, H-6), 2.62 (s, 3H, Me), 2.48 (s, 3H, Me); ¹³C NMR (150 MHz, CDCl₃) δ 163.0, 162.6, 147.8 (overlapping of 2 carbon signals), 146.8, 110.6, 101.4, 24.7, 17.0; MS (ESI) m/z 190 [M – H][–]; Found: C, 56.72; H, 4.69; N, 22.09. C₉H₉N₃O₂ requires C, 56.54; H, 4.75; N, 21.98%.

General procedure for the synthesis of amides 2a and 2b. To a solution of **5** (500 mg, 2.6 mmol) and the appropriate amine (4.0 mmol) in dry CH₂Cl₂ (100 mL) and DMF (10 mL), *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride (EDC) (1.0 g, 5.2 mmol) and 1-hydroxybenzotriazole (HOBt) (350 mg, 2.6 mmol) were added and the mixture was stirred at room temperature for 4 h. Then the reaction mixture was washed with 0.5 N HCl, 10% NaHCO₃ solution, and brine. After drying over sodium sulfate, the organic solution was concentrated in vacuo and the residue was purified as reported below.

***N*-(4-Bromobenzyl)-5,7-dimethylpyrazolo[1,5-*a*]pyrimidine-3-carboxamide (2a).** Purified by trituration with hexane/Et₂O. White solid (650 mg, 70%); mp 169-172 °C; FT-IR $\nu_{\text{max}}/\text{cm}^{-1}$ 3328 (NH), 1649 (C=O), 1549, 771; ¹H NMR (400 MHz, CDCl₃) δ 8.59 (s, 1H, H-2), 8.43 (br s, 1H, NH), 7.39 (d, *J* 8.3 Hz, 2H, Ph), 7.22 (d, *J* 8.3 Hz, 2H, Ph), 6.64 (s, 1H, H-6), 4.61 (d, *J* 5.6 Hz, 2H, CH₂), 2.72 (s, 3H, Me), 2.53 (s, 3H, Me); ¹³C NMR (100 MHz, CDCl₃) δ 162.8, 161.1, 147.0, 146.1, 146.0, 138.3, 131.6 (2 equivalent carbons), 129.2 (2 equivalent carbons), 120.9, 109.7, 104.6, 42.3, 24.8, 17.0; MS (ESI) m/z 359 (100%), 361 (98%) [M + H]⁺; Found: C, 53.68; H, 4.17; N, 15.47. C₁₆H₁₅BrN₄O requires C, 53.50; H, 4.21; N, 15.60%.

***N*-[(6-Chloropyridin-3-yl)methyl]-5,7-dimethylpyrazolo[1,5-*a*]pyrimidine-3-carboxamide (2b).** Purified by flash chromatography (silica, EtOAc/hexane 2:1 to 4:1). White crystals (534 mg, 65%); mp 157-160 °C; FT-IR $\nu_{\text{max}}/\text{cm}^{-1}$ 3324 (NH), 2918, 1650 (C=O), 1551, 1458, 773; ¹H NMR (400 MHz, CDCl₃) δ 8.53 (s, 1H, H-2), 8.43

(br s, 1H, NH), 8.34 (s, 1H, Py), 7.68 (d, *J* 8.2 Hz, 1H, Py), 7.21 (d, *J* 8.2 Hz, 1H, Py), 6.64 (s, 1H, H-6), 4.63 (d, *J* 5.9 Hz, 2H, CH₂), 2.71 (s, 3H, Me), 2.53 (s, 3H, Me). ¹³C NMR (100 MHz, CDCl₃) δ 162.8, 161.3, 150.1, 148.8, 147.0, 146.0, 145.9, 138.4, 134.0, 124.1, 109.8, 104.2, 39.6, 24.7, 17.0; MS (ESI) *m/z* 316 (100%), 318 (32%) [M + H]⁺; Found: C, 56.90; H, 4.40; N, 21.99. C₁₅H₁₄ClN₅O requires C, 57.06; H, 4.47; N, 22.18%.

General procedure for the synthesis of compounds 2d, 2e, 2f. In a 25 mL round bottom flask **2a** or **2b** (0.63 mmol) was dissolved in 1,4-dioxane (3-4 mL) under nitrogen. Then the appropriate arylboronic acid (1.9 mmol, 3 eq), PPh₃ (50 mg, 0.19 mmol, 3 eq), Pd(OAc)₂ (14 mg, 0.063 mmol, 0.1 eq) were added successively, followed by addition of EtOH (2 mL) and 1 M Na₂CO₃ (1.27 mL, 1.27 mmol, 2 eq). The mixture was refluxed for 6 h, then cooled to room temperature and filtered through celite. The yellow solution was dried over sodium sulfate and concentrated in vacuo to leave a solid residue which was purified as described below.

***N*-[(2,3'-Bipyridin)-5-ylmethyl]-5,7-dimethylpyrazolo[1,5-*a*]pyrimidine-3-carboxamide (2d).** Prepared from **2b** and 3-pyridinylboronic acid. Purified by flash chromatography (silica, EtOAc to EtOAc/MeOH 9:1). White solid (152 mg, 67% yield); mp 184–186 °C; FT-IR *v*_{max}/cm⁻¹ 3324 (NH), 2922, 1651 (C=O), 1557, 1374, 707; ¹H NMR (400 MHz, CDCl₃) δ 9.20 (s, 1H, Py), 8.72 (s, 1H, H-2), 8.61-8.52 (m, 4H, Py and NH), 7.87 (d, *J* 8.1 Hz, 1H, Py), 7.71 (d, *J* 8.1 Hz, 1H, Py), 7.59-7.52 (m, 1H, Py), 6.66 (s, 1H, H-6), 4.74 (d, *J* 5.7 Hz, 2H, CH₂), 2.73 (s, 3H, Me), 2.56 (s, 3H, Me); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 162.2, 162.0, 152.9, 150.2, 149.5, 148.1, 147.5, 145.8, 145.5, 136.8, 135.4, 134.4, 134.2, 124.2, 120.8, 110.6, 104.4, 24.8, 16.9, one more signal overlapped with solvent; MS (ESI) *m/z* 359 [M + H]⁺; Found: C, 67.22; H, 5.00; N, 23.36. C₂₀H₁₈N₆O requires C, 67.02; H, 5.06; N, 23.45%.

***N*-[[6-(3-Acetamidophenyl)pyridin-3-yl]methyl]-5,7-dimethylpyrazolo[1,5-*a*]pyrimidine-3-carboxamide (2e).** Prepared from **2b** and 3-acetamidophenylboronic acid. Purified by flash chromatography (silica, EtOAc to EtOAc/MeOH 9:1). White solid (135 mg, 34% yield); mp 232-233 °C; FT-IR *v*_{max}/cm⁻¹ 3308 (NH), 1680 (C=O), 1636 (C=O), 1549, 1471, 707; ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.97 (s, 1H, AcNH), 8.59 (s, 1H, Py), 8.50 (t, *J* 5.8 Hz, 1H, NH-CH₂), 8.45 (s, 1H, H-2), 8.19 (s, 1H, Py), 7.77 (s, 2H, Ph), 7.67-7.57 (m, 2H, Ph and Py), 7.30 (t, *J* 7.9 Hz, 1H, Ph), 7.02 (s, 1H, H-6), 4.59 (d, *J* 5.9 Hz, 2H, CH₂), 2.65 (s, 3H, Me), 2.52 (s, 3H, Me), 1.99 (s, 3H, MeCO); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 168.9, 162.2, 162.0, 155.0, 149.1, 147.4, 145.8, 145.5, 140.3, 139.4, 136.6, 134.7, 129.5, 121.5, 120.3, 120.0, 117.5, 110.5, 104.4, 40.0 (overlapped with solvent), 24.8, 24.5, 16.9; MS (ESI) *m/z* 415 [M + H]⁺; Found: C, 66.80; H, 5.29; N, 20.15. C₂₃H₂₂N₆O₂ requires C, 66.65; H, 5.35; N, 20.28%.

5,7-Dimethyl-*N*-[[6-[4-(trifluoromethoxy)phenyl]pyridin-3-yl]methyl]pyrazolo[1,5-*a*]pyrimidine-3-carboxamide (2f). Prepared from **2b** and 4-(trifluoromethoxy)phenylboronic acid. Purified by flash chromatography (silica, EtOAc/hexane 4:1). Colorless solid (136 mg, 54% yield); mp 206–207 °C; FT-IR *v*_{max}/cm⁻¹ 3309 (NH), 1653 (C=O), 1545, 1474, 1265-1159 (C–F); ¹H NMR (400 MHz, CDCl₃) δ 8.69 (s, 1H, Ph), 8.57 (s, 1H, H-2), 8.51 (t, *J* 5.5 Hz, 1H, NH), 7.98 (d, *J* 8.7 Hz, 2H, Ph), 7.90 (d, *J* 8.0 Hz, 1H, Py), 7.66 (d, *J* 8.2 Hz, 1H, Py), 7.25 (d, *J* 8.4 Hz, 2H, Ph), 6.65 (s, 1H, H-6), 4.73 (d, *J* 6.0 Hz, 2H, CH₂), 2.73 (s, 3H, Me), 2.55 (s, 3H, Me); ¹³C NMR (100 MHz, CDCl₃) δ 162.8, 161.2, 154.5, 149.9, 148.5, 147.0, 146.0, 145.9, 137.2, 136.9, 134.0, 128.4 (overlapped signals for 3 carbons), 121.7 (signal for C–F coupling), 121.0 (signal for C–F coupling and 1 more carbon signal), 120.4 (signal for C–F coupling and 1 more carbon signal), 119.2 (signal for C–F coupling), 109.7, 104.4, 40.1, 24.7, 16.9; MS (ESI) *m/z* 442 [M + H]⁺; Found: C, 60.08; H, 4.18; N, 15.70. C₂₂H₁₈F₃N₅O₂ requires C, 59.86; H, 4.11; N, 15.87%.

Synthesis of *N*-[[4'-(hydroxymethyl)-(1,1'-biphenyl)-4-yl]methyl]-5,7-dimethylpyrazolo[1,5-*a*]pyrimidine-3-carboxamide (2c). Reaction of **2a** (200 mg, 0.56 mmol) with 3-formylboronic acid according to the general procedure reported above afforded *N*-[[4'-formyl-(1,1'-biphenyl)-4-yl]methyl]-5,7-dimethylpyrazolo[1,5-*a*]pyrimidine-3-carboxamide (**6**) (135 mg, 63%) after purification of the crude by flash chromatography (silica,

EtOAc/hexane 2:1). The aldehyde **6** (100 mg, 0.26 mmol) was dissolved in MeOH (20 mL) and treated with NaBH₄ (10 mg, 0.26 mmol) at room temperature for 4 h. The reaction mixture was concentrated and diluted with water and EtOAc. The organic layer was separated, dried over sodium sulfate, filtered, and evaporated to dryness. The residue was recrystallized from MeOH/EtOAc to give **2c** (77 mg, 77%, 48% overall yield from **2a**). White solid; mp 223-225 °C; FT-IR $\nu_{\text{max}}/\text{cm}^{-1}$ 3323 (NH), 1647 (C=O), 1556, 1425, 1375; ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.45 (superimposed signals, 2H, H-2 and NH), 7.62-7.48 (m, 4H, Ph), 7.36 (d, *J* 7.8 Hz, 2H, Ph), 7.31 (d, *J* 7.8 Hz, 2H, Ph), 7.02 (s, 1H, H-6), 5.11 (br s, 1H, OH), 4.57 (d, *J* 5.6 Hz, 2H, CH₂-NH), 4.45 (s, 2H, CH₂-OH), 2.66 (s, 3H, Me), 2.52 (s, 3H, Me); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 162.0, 161.9, 147.5, 145.8, 145.5, 142.2, 139.2, 139.1, 138.8, 128.2 (2 equivalent carbons), 127.5 (2 equivalent carbons), 127.0 (2 equivalent carbons), 126.7 (2 equivalent carbons), 110.5, 104.5, 63.1, 42.1, 24.8, 16.9; MS (ESI) *m/z* 387 [M + H]⁺; Found: C, 71.68; H, 5.66; N, 14.69. C₂₃H₂₂N₄O₂ requires C, 71.48; H, 5.74; N, 14.50%.

Molecular modeling. The LigPrep routine of Maestro was applied to convert 1D SMILES notation into a low energy 3D structure of the studied compound.¹³ Next, a systematic torsional sampling of the rotatable bonds (namely, a systematic pseudo-Monte Carlo conformational search within the ConfGen routine¹⁴) was performed, using the OPLS3e force field and water, chloroform, or DMSO as the solvent. Conformations within 25 kcal/mol above the global minimum were minimized with 1000 iterations of the Polak-Ribiere conjugate gradient algorithm.

Acknowledgements

Authors acknowledge the partial support by MIUR Progetto *Dipartimenti di Eccellenza 2018-2022*, grant n. L. 232/2016.

Supplementary Material

Copies of the ¹³C NMR spectra and HPLC traces of compounds **2a-f** are given in the Supplementary Material file associated with this manuscript.

References

1. Diana, P.; Cirrincione, G. *Biosynthesis of Heterocycles: from isolation to gene cluster*; John Wiley & Sons, Inc.: Hoboken, NJ, 2015.
2. Li Petri, G.; Spanò, V.; Spatola, R.; Holl, R.; Raimondi, M. V.; Barraja, P.; Montalbano, A. *Eur. J. Med. Chem.* **2020**, *208*, 112783.
doi.org/10.1016/j.ejmech.2020.112783
3. Karrouchi, K.; Radi, S.; Ramli, Y.; Taoufik, J.; Mabkhot, Y. N.; Al-aizari, F. A.; Ansar, M. *Molecules* **2018**, *23*, 134-220.
doi.org/10.3390/molecules23010134
4. Silvestri, R.; Cascio, M. G.; La Regina, G.; Piscitelli, F.; Lavecchia, A.; Brizzi, A.; Pasquini, S.; Botta, M.; Novellino, E.; Di Marzo, V.; Corelli, F. *J. Med. Chem.* **2008**, *51*, 1560-1576.

doi.org/10.1021/jm070566z

5. Silvestri, R.; Ligresti, A.; La Regina, G.; Piscitelli, F.; Gatti, V.; Brizzi, A.; Pasquini, S.; Lavecchia, A.; Allarà, M.; Fantini, N.; Carai, M. A. M.; Novellino, E.; Colombo, G.; Di Marzo, V.; Corelli, F. *Bioorg. Med. Chem.* **2009**, *17*, 5549-5564.
[doi:10.1016/j.bmc.2009.06.027](https://doi.org/10.1016/j.bmc.2009.06.027)
6. Silvestri, R.; Ligresti, A.; La Regina, G.; Piscitelli, F.; Gatti, V.; Lavecchia, A.; Brizzi, A.; Pasquini, S.; Allarà, M.; Fantini, N.; Carai, M. A. M.; Bigogno, C.; Rozio, M. G.; Sinisi, R.; Novellino, E.; Colombo, G.; Di Marzo, V.; Dondio, G.; Corelli, F. *Eur. J. Med. Chem.* **2010**, *45*, 5878-5886.
doi.org/10.1016/j.ejmech.2010.09.053
7. Piscitelli, F.; Ligresti, A.; La Regina, G.; Gatti, V.; Brizzi, A.; Pasquini, S.; Allarà, M.; Carai, M. A. M.; Novellino, E.; Colombo, G.; Di Marzo, V.; Corelli, F.; Silvestri, R. *Eur. J. Med. Chem.* **2011**, *46*, 5641-5653.
doi.org/10.1016/j.ejmech.2011.09.037
8. Mugnaini, C.; Sannio, F.; Brizzi, A.; Del Prete, R.; Simone, T.; Ferraro, T.; De Luca, F.; Corelli, F.; Docquier, J.-D. *ACS Med. Chem. Lett.* **2020**, *11*, 899-905.
doi.org/10.1021/acsmchemlett.9b00674
9. Mikami, S.; Sasaki, S.; Asano, Y.; Ujikawa, O.; Fukumoto, S.; Nakashima, K.; Oki, H.; Kamiguchi, N.; Imada, H.; Iwashita, H.; Taniguchi, T. *J. Med. Chem.* **2017**, *60*, 7658-7676.
doi.org/10.1021/acs.jmedchem.7b00709
10. Lu, X.; Tang, J.; Cui, S.; Wan, B.; Franzblau, S. G.; Zhang, T.; Zhang, X.; Ding, K. *Eur. J. Med. Chem.* **2017**, *125*, 41-48.
doi.org/10.1016/j.ejmech.2016.09.030
11. Grabowski, S. J. *Understanding Hydrogen Bonds: Theoretical and Experimental Views*. Theoretical and Computational Chemistry Series No. 19. Hydrogen Bond – Definitions, criteria of existence and various types. Chapter 1, pp. 1-40, Royal Society of Chemistry, 2021.
12. Patnaik, S.; Zheng, W.; Choi, J. H.; Motabar, O.; Southall, N.; Westbroek, W.; Lea, W. A.; Velayati, A.; Goldin, E.; Sidransky, E.; Leister, W.; Marugan, J. J. *J. Med. Chem.* **2012**, *55*, 5734-5748.
doi.org/10.1021/jm300063b
13. Maestro version 11.9, release 2019-1, Schrodinger, LLC, New York, NY, 2019.
14. Watts, K. S.; Dalal, P.; Murphy, R. B.; Sherman, W.; Friesner, R. A.; Shelley, J. C. *J. Chem. Inf. Model.* **2010**, *50*, 534-546.
doi.org/10.1021/ci100015j

This paper is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>)